GlassScriptPhysician profile
Andrew S Nik
NPI 1316177520
$13,760.94
in general payments reported to CMS, 2019-2025
64 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 79% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $1,452 · 2021: $2,468 · 2022: $2,013 · 2023: $1,964 · 2024: $2,769 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,655 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,655.36 |
| Education | $184.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,165.95 | 2021-2025 | |
| Biogen, INC. | $925.30 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Acadia Pharmaceuticals INC | $907.10 | 2019-2025 | Nuplazid, Daybue |
| Supernus Pharmaceuticals, INC. | $823.49 | 2019-2023 | Oxtellar Xr |
| Allergan, INC. | $744.75 | 2019-2022 | |
| Ucb, INC. | $563.03 | 2019-2025 | Briviact, Nayzilam |
| Sk Life Science, INC. | $559.08 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $502.88 | 2021-2025 | Ultomiris |
| Pfizer INC. | $465.35 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $404.42 | 2019-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $357.80 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $329.32 | 2019-2022 | |
| Mdd US Operations, LLC | $313.93 | 2019-2025 | Gocovri, Gocovri, Qelbree |
| Lundbeck LLC | $304.90 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $224.62 | 2019-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $209.41 | 2020-2025 | Amyvid, Kisunla, Emgality |
| Argenx US, INC. | $173.07 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Avion Pharmaceuticals | $159.06 | 2022-2023 | Dhivy |
| Abbott Laboratories | $132.88 | 2019-2024 | Infinity |
| Corium, LLC | $128.46 | 2022-2023 | Adlarity |
| Eisai INC. | $127.09 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.70 | 2022 | |
| Amneal Pharmaceuticals LLC | $114.45 | 2023-2025 | Rytary, Crexont |
| Amgen INC. | $110.26 | 2019-2025 | Uplizna |
| Horizon Therapeutics Plc | $108.53 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $105.44 | 2019-2021 | |
| Genzyme Corporation | $104.51 | 2019-2022 | |
| Boston Scientific Corporation | $96.16 | 2021-2025 | General - Dbs |
| Genentech USA, INC. | $94.18 | 2020-2025 | Ocrevus, Ocrevus Zunovo |
| Livanova USA, INC. | $88.98 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Neurelis, INC. | $86.05 | 2022-2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $79.93 | 2021-2024 | Andexxa |
| Harmony Biosciences LLC | $74.27 | 2022-2023 | Wakix |
| Aquestive Therapeutics, INC. | $68.47 | 2019-2021 | |
| Greenwich Biosciences, INC. | $67.91 | 2021 | |
| Zyla Life Sciences, INC. | $61.57 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $59.28 | 2022-2024 | Ingrezza |
| Portola Pharmaceuticals, LLC | $56.76 | 2019 | |
| Kyowa Kirin, INC. | $47.97 | 2021-2024 | Nourianz |
| Upsher-Smith Laboratories LLC | $47.58 | 2019-2020 | |
| Octapharma USA, INC. | $46.54 | 2024-2025 | Panzyga |
| Averitas Pharma INC. | $45.04 | 2024 | Qutenza |
| Acorda Therapeutics, INC | $42.48 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $37.95 | 2024-2025 | Rexulti |
| Ge Healthcare | $36.58 | 2024 | |
| Banner Life Sciences, LLC | $35.19 | 2024 | |
| Jazz Pharmaceuticals INC. | $34.84 | 2024 | |
| Assertio Therapeutics, INC. | $32.81 | 2020 | |
| Axsome Therapeutics, INC. | $29.25 | 2025 | Symbravo |
| Merz Pharmaceuticals, LLC | $26.63 | 2025 | Xeomin |
| Cycle Pharmaceuticals INC | $25.93 | 2025 | Bafiertam |
| Alnylam Pharmaceuticals INC. | $24.40 | 2024 | Amvuttra |
| Noctrix Health, INC. | $24.34 | 2025 | Nidra |
| Tanabe Pharma America, INC. | $24.21 | 2024 | |
| Avanir Pharmaceuticals, INC. | $23.37 | 2019 | |
| Tg Therapeutics, INC. | $21.61 | 2024 | |
| Neuropace, INC. | $19.43 | 2024 | |
| Aucta Pharmaceuticals, INC. | $18.49 | 2025 | Motpoly Xr |
| Janssen Pharmaceuticals, INC | $17.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.11 | 2024 | Hyqvia |
| Arbor Pharmaceuticals, INC. | $16.48 | 2019 | |
| Janssen Biotech, INC. | $16.32 | 2025 | |
| Grt US Holding, INC. | $14.13 | 2022 | |
| Csl Behring | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Nik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.